Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel + Nexavar vs Docetaxel + Placebo in HER2-negative Metastatic Breast Cancer
DRKS00003947Phase 2Recruiting
- Sponsor
- Heidelberg University Hospital
- Start
- Dec 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sorafenib in breast cancer (2 arms), sponsored by Heidelberg University Hospital. Started Dec 2012; status: recruiting.
02
Drugs
sorafenib
03
Conditions
breast cancer
Beyond the preview
Go deeper on DRKS00003947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00003947.